Atamparib is under clinical development by Ribon Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Atamparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Atamparib overview

Atamparib (RBN-2397) is under development for the treatment of advanced squamous non-small cell lung carcinoma, squamous cell carcinoma of the lung, mantle cell lymphoma, HER2 negative breast cancer, head and neck squamous cell carcinoma and other solid tumors. It is administered by oral route as tablet formulation. The drug candidate is a new chemical entity. The drug candidate acts by targeting monoPARPs (poly ADP-ribose polymerases) PARP7. 

Ribon Therapeutics overview

Ribon Therapeutics is a clinical-stage biopharmaceutical company that develops novel small molecule therapeutics. It utilizes the BEACON+ (blocking the enzyme activity component of NAD+) platform to discover and develop drugs. The company’s pipeline products include RBN-2397, a small molecule inhibitor of the monoPARP PARP7, that treats solid tumors; RBN-3143, a first-in-class, oral small molecule inhibitor of PARP14 inhibitor that targets inflammatory diseases; and CD38 inhibitor early program. Ribon Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Atamparib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.